Cormorant Asset Management, LP
An institutional investment manager in BOSTON, MA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1583977.
- Reported value$1.95bn
- Positions50
Holdings: 50 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 214 | 11.0% | 640,000 | Reduced−245,500 | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 136 | 7.0% | 17,878,594 | Unchanged | |
| Parabilis Medicines IncPBLS | COM | 698955101 | 126 | 6.5% | 4,615,612 | New+4,615,612 | |
| Rapport Therapeutics IncRAPP | COM | 75383L102 | 111 | 5.7% | 2,657,521 | Reduced−300,000 | |
| Erasca IncERAS | COM | 29479A108 | 110 | 5.6% | 6,000,000 | Added+200,000 | |
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 102 | 5.2% | 2,510,000 | Reduced−750,000 | |
| Eyepoint IncEYPT | COM NEW | 30233G209 | 100 | 5.1% | 7,000,000 | Reduced−1,265,000 | |
| Alumis IncALMS | COM | 022307102 | 92.5 | 4.7% | 3,285,596 | Reduced−663,645 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 90.0 | 4.6% | 675,000 | Reduced−85,000 | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 73.1 | 3.7% | 750,000 | Reduced−200,000 | |
| Bright Minds Biosciences IncDRUG | COM NEW | 10919W405 | 63.2 | 3.2% | 900,000 | Reduced−159,331 | |
| Moonlake ImmunotherapeuticsMLTX | CLASS A ORD | 61559X104 | 62.4 | 3.2% | 3,205,433 | Reduced−1,275,000 | |
| Bioage Labs IncBIOA | COM | 09077V100 | 58.6 | 3.0% | 2,390,605 | Reduced−500,000 | |
| Oruka Therapeutics IncORKA | COM | 687604108 | 50.8 | 2.6% | 533,340 | Unchanged | |
| Adlai Nortye LtdANL | SPONSORED ADS | 00704R109 | 45.7 | 2.3% | 3,978,229 | Added+1,080,372 | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 41.0 | 2.1% | 550,000 | Reduced−300,000 | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 40.6 | 2.1% | 1,300,000 | Reduced−125,000 | |
| Biohaven Ltd | COM | G1110E107 | 38.8 | 2.0% | 2,610,000 | Added+850,000 | |
| Agomab Therapeutics NVAGMB | SPONSORED ADS | 00860C102 | 32.0 | 1.6% | 2,465,348 | Unchanged | |
| MBX Biosciences IncMBX | COM | 55287L101 | 30.4 | 1.6% | 550,000 | Reduced−570,000 | |
| Climb Bio IncCLYM | COM | 28658R106 | 27.5 | 1.4% | 2,106,000 | New+2,106,000 | |
| Olema Pharmaceuticals IncOLMA | COM | 68062P106 | 26.9 | 1.4% | 2,150,000 | Reduced−1,750,000 | |
| Damora Therapeutics Inc | COM | 36322Q206 | 26.0 | 1.3% | 1,000,000 | Reduced−525,000 | |
| Pharvaris N V | COM | N69605108 | 25.9 | 1.3% | 750,000 | Reduced−250,000 | |
| Corbus Pharmaceuticals HoldingsCRBP | COM NEW | 21833P301 | 22.0 | 1.1% | 2,344,971 | Unchanged | |
| Spyre Therapeutics IncSYRE | COM NEW | 00773J202 | 20.0 | 1.0% | 225,000 | New+225,000 | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 18.8 | 1.0% | 400,000 | New+400,000 | |
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 16.9 | 0.9% | 500,000 | Reduced−450,000 | |
| Roivant Sciences Ltd | SHS | G76279101 | 16.8 | 0.9% | 475,000 | Reduced−275,000 | |
| Cabaletta Bio IncCABA | COM | 12674W109 | 15.6 | 0.8% | 5,000,000 | Reduced−500,000 | |
| Helix Acquisition Corp III | USD CL A ORD SHS | G4444S107 | 13.8 | 0.7% | 1,297,500 | Unchanged | |
| Ascendis Pharma A/S | ORD SHS | K08588103 | 13.3 | 0.7% | 50,000 | New+50,000 | |
| Kailera Therapeutics IncKLRA | COMMON STOCK | 482931102 | 12.1 | 0.6% | 550,000 | New+550,000 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 8.0 | 0.4% | 75,000 | Reduced−115,000 | |
| Faeth Therapeutics IncFTH | COM NEW | 81728A207 | 7.7 | 0.4% | 1,028,242 | Added+722,020 | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 7.6 | 0.4% | 150,000 | New+150,000 | |
| Tarsus Pharmaceuticals IncTARS | COM | 87650L103 | 6.3 | 0.3% | 100,000 | Reduced−125,000 | |
| Ibio IncIBIO | COM NEW | 451033708 | 6.2 | 0.3% | 3,570,000 | New+3,570,000 | |
| Crinetics Pharmaceuticals in | COM | 22663K107 | 4.7 | 0.2% | 125,000 | Reduced−125,000 | |
| Arcutis Biotherapeutics IncARQT | COM | 03969K108 | 4.6 | 0.2% | 175,000 | Reduced−275,000 | |
| Arrowhead Pharmaceuticals inARWR | COM | 04280A100 | 4.1 | 0.2% | 50,000 | Reduced−50,000 | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 4.0 | 0.2% | 75,000 | Reduced−100,000 | |
| Research Alliance Corp III | ORD SHS CL A | G75226103 | 4.0 | 0.2% | 370,000 | New+370,000 | |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 3.9 | 0.2% | 100,000 | Reduced−100,000 | |
| Altimmune IncALT | COM NEW | 02155H200 | 3.8 | 0.2% | 1,250,000 | New+1,250,000 | |
| Amylyx Pharmaceuticals IncAMLX | COM | 03237H101 | 3.6 | 0.2% | 200,000 | Reduced−150,000 | |
| Odyssey Therapeutics IncODTX | COMMON STOCK | 67613T104 | 3.3 | 0.2% | 175,000 | New+175,000 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 2.9 | 0.1% | 50,000 | Reduced−50,000 | |
| Boundless Bio IncBOLD | COM | 10170A100 | 2.5 | 0.1% | 1,000,000 | New+1,000,000 | |
| Quince Therapeutics IncIRLA | COM | 22053A305 | 0.1 | <0.1% | 5,498 | New+5,498 |
Sold out: 10 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 0.0 | 0.0% | 0 | Sold out−95,000 | |
| Axsome Therapeutics Inc.AXSM | COM | 05464T104 | 0.0 | 0.0% | 0 | Sold out−50,000 | |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−1,050,000 | |
| Context Therapeutics IncCNTX | COM | 21077P108 | 0.0 | 0.0% | 0 | Sold out−529,550 | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 0.0 | 0.0% | 0 | Sold out−750,000 | |
| Monte Rosa Therapeutics IncGLUE | COM | 61225M102 | 0.0 | 0.0% | 0 | Sold out−400,000 | |
| Olema Pharmaceuticals IncOLMA | COM | 68062P106 | 0.0 | 0.0% | 0 | Call | Sold out−500,000 |
| Rallybio CorpRLYB | COM | 75120L209 | 0.0 | 0.0% | 0 | Sold out−400,000 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−300,000 | |
| Zura Bio Ltd | CLASS A ORD SHS | G9TY5A101 | 0.0 | 0.0% | 0 | Sold out−1,450,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001583977-26-000007 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.